Charles River Laboratories International, Inc. (CRL) EV/Sales Ratio: 3.00x
Is Charles River Laboratories International, Inc.’s EV/Sales ratio high or low?
Charles River Laboratories International, Inc.'s EV/Sales ratio of 3.00x is 21% below its 5-year average of 3.79x, near the low end of its 5-year range (1.88x–8.04x).
As of Friday, June 12, 2026. 7.40% above its 12-month average of 2.79x.
CRL EV/Sales Ratio Chart
CRL Average EV/Sales Ratio Chart
CRL Current vs Average EV/Sales Ratio Chart
CRL EV/Sales Ratio Metrics
EV/SALES RATIO
3.00x
EV/SALES RATIO AVG TTM
2.79x
EV/SALES RATIO AVG 3Y
3.02x
EV/SALES RATIO AVG 5Y
3.79x
EV/SALES RATIO AVG 10Y
3.80x
EV/SALES RATIO AVG 15Y
3.40x
EV/SALES RATIO AVG 20Y
3.23x
CURRENT VS TTM AVG
+7.40%
CURRENT VS 3Y AVG
-0.80%
CURRENT VS 5Y AVG
-20.88%
CURRENT VS 10Y AVG
-21.01%
CURRENT VS 15Y AVG
-11.80%
CURRENT VS 20Y AVG
-7.04%
CRL Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 3.00x | 2.79x | 3.02x | 3.79x |
| Tempus AI, Inc. (TEM) | $8.65B | 6.72x | 11.47x | 12.18x | 12.18x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 3.38x | 3.41x | 3.67x | 4.57x |
| Baxter International Inc. (BAX) | $10.70B | 1.61x | 1.72x | 2.17x | 2.64x |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 3.17x | 4.73x | 4.20x | 4.27x |
| Align Technology, Inc. (ALGN) | $12.64B | 2.85x | 2.73x | 4.07x | 5.91x |
| Solventum Corporation (SOLV) | $13.72B | 2.23x | 2.19x | 2.26x | 2.26x |
| Hologic, Inc. (HOLX) | $16.97B | 4.25x | 4.02x | 4.39x | 4.15x |
| 23andMe Holding Co. (ME) | $15.31M | 0.02x | 0.35x | 0.71x | 3.53x |
| Moderna, Inc. (MRNA) | $19.70B | 8.54x | 5.96x | 5.02x | 6.82x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Charles River Laboratories International, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Charles River Laboratories International, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
- The EV/Sales ratio for CRL stock is 3.00x.
- Is Charles River Laboratories International, Inc.'s EV/Sales ratio high or low?
- Charles River Laboratories International, Inc.'s EV/Sales ratio of 3.00x is 21% below its 5-year average of 3.79x, near the low end of its 5-year range (1.88x–8.04x).
- What is the TTM average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
- The TTM average EV/Sales ratio for CRL stock is 2.79x.
- What is the 3Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
- The 3Y average EV/Sales ratio for CRL stock is 3.02x.
- What is the 5Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
- The 5Y average EV/Sales ratio for CRL stock is 3.79x.
- What is the 10Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
- The 10Y average EV/Sales ratio for CRL stock is 3.80x.
- What is the 15Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
- The 15Y average EV/Sales ratio for CRL stock is 3.40x.
- What is the 20Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
- The 20Y average EV/Sales ratio for CRL stock is 3.23x.
Charles River Laboratories International, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-11 | 3.00x |
| 2026-06-10 | 2.98x |
| 2026-06-09 | 3.02x |
| 2026-06-08 | 2.98x |
| 2026-06-05 | 2.92x |
| 2026-06-04 | 2.97x |
| 2026-06-03 | 2.90x |
| 2026-06-02 | 2.84x |
| 2026-06-01 | 2.92x |
| 2026-05-29 | 2.91x |
| 2026-05-28 | 2.92x |
| 2026-05-27 | 2.71x |
| 2026-05-26 | 2.62x |
| 2026-05-22 | 2.66x |
| 2026-05-21 | 2.64x |
| 2026-05-20 | 2.61x |
| 2026-05-19 | 2.56x |
| 2026-05-18 | 2.53x |
| 2026-05-15 | 2.54x |
| 2026-05-14 | 2.65x |
| 2026-05-13 | 2.69x |
| 2026-05-12 | 2.76x |
| 2026-05-11 | 2.76x |
| 2026-05-08 | 2.87x |
| 2026-05-07 | 2.92x |
| 2026-05-06 | 2.94x |
| 2026-05-05 | 2.98x |
| 2026-05-04 | 2.82x |
| 2026-05-01 | 2.74x |
| 2026-04-30 | 2.76x |
| 2026-04-29 | 2.72x |
| 2026-04-28 | 2.75x |
| 2026-04-27 | 2.81x |
| 2026-04-24 | 2.79x |
| 2026-04-23 | 2.77x |
| 2026-04-22 | 2.98x |
| 2026-04-21 | 2.95x |
| 2026-04-20 | 2.98x |
| 2026-04-17 | 2.96x |
| 2026-04-16 | 2.88x |
| 2026-04-15 | 2.92x |
| 2026-04-14 | 2.91x |
| 2026-04-13 | 2.90x |
| 2026-04-10 | 2.86x |
| 2026-04-09 | 2.86x |
| 2026-04-08 | 2.86x |
| 2026-04-07 | 2.79x |
| 2026-04-06 | 2.77x |
| 2026-04-02 | 2.84x |
| 2026-04-01 | 2.85x |
| 2026-03-31 | 2.82x |
| 2026-03-30 | 2.67x |
| 2026-03-27 | 2.66x |
| 2026-03-26 | 2.73x |
| 2026-03-25 | 2.74x |
| 2026-03-24 | 2.66x |
| 2026-03-23 | 2.65x |
| 2026-03-20 | 2.59x |
| 2026-03-19 | 2.59x |
| 2026-03-18 | 2.64x |
| 2026-03-17 | 2.59x |
| 2026-03-16 | 2.57x |
| 2026-03-13 | 2.62x |
| 2026-03-12 | 2.58x |
| 2026-03-11 | 2.78x |
| 2026-03-10 | 2.76x |
| 2026-03-09 | 2.88x |
| 2026-03-06 | 2.85x |
| 2026-03-05 | 2.93x |
| 2026-03-04 | 2.91x |
| 2026-03-03 | 2.86x |
| 2026-03-02 | 2.90x |
| 2026-02-27 | 2.90x |
| 2026-02-26 | 2.86x |
| 2026-02-25 | 2.76x |
| 2026-02-24 | 2.75x |
| 2026-02-23 | 2.71x |
| 2026-02-20 | 2.78x |
| 2026-02-19 | 2.72x |
| 2026-02-18 | 2.65x |
| 2026-02-17 | 2.55x |
| 2026-02-13 | 2.58x |
| 2026-02-12 | 2.55x |
| 2026-02-11 | 2.64x |
| 2026-02-10 | 2.83x |
| 2026-02-09 | 2.88x |
| 2026-02-06 | 2.93x |
| 2026-02-05 | 2.86x |
| 2026-02-04 | 3.08x |
| 2026-02-03 | 3.08x |
| 2026-02-02 | 3.22x |
| 2026-01-30 | 3.19x |
| 2026-01-29 | 3.20x |
| 2026-01-28 | 3.27x |
| 2026-01-27 | 3.30x |
| 2026-01-26 | 3.33x |
| 2026-01-23 | 3.30x |
| 2026-01-22 | 3.35x |
| 2026-01-21 | 3.39x |
| 2026-01-20 | 3.28x |
| 2026-01-16 | 3.30x |
| 2026-01-15 | 3.35x |
| 2026-01-14 | 3.26x |
| 2026-01-13 | 3.29x |
| 2026-01-12 | 3.29x |
| 2026-01-09 | 3.32x |
| 2026-01-08 | 3.25x |
| 2026-01-07 | 3.27x |
| 2026-01-06 | 3.26x |
| 2026-01-05 | 3.16x |
| 2026-01-02 | 3.09x |
| 2025-12-31 | 3.05x |
| 2025-12-30 | 3.08x |
| 2025-12-29 | 3.10x |
| 2025-12-26 | 3.10x |
| 2025-12-24 | 3.10x |
| 2025-12-23 | 3.09x |
| 2025-12-22 | 3.10x |
| 2025-12-19 | 3.02x |
| 2025-12-18 | 2.98x |
| 2025-12-17 | 3.01x |
| 2025-12-16 | 3.00x |
| 2025-12-15 | 3.04x |
| 2025-12-12 | 2.97x |
| 2025-12-11 | 2.99x |
| 2025-12-10 | 3.00x |
| 2025-12-09 | 2.89x |
| 2025-12-08 | 2.90x |
| 2025-12-05 | 2.87x |
| 2025-12-04 | 2.86x |
| 2025-12-03 | 2.87x |
| 2025-12-02 | 2.75x |
| 2025-12-01 | 2.77x |
| 2025-11-28 | 2.79x |
| 2025-11-26 | 2.80x |
| 2025-11-25 | 2.79x |
| 2025-11-24 | 2.70x |
| 2025-11-21 | 2.66x |
| 2025-11-20 | 2.59x |
| 2025-11-19 | 2.59x |
| 2025-11-18 | 2.60x |
| 2025-11-17 | 2.60x |
| 2025-11-14 | 2.66x |
| 2025-11-13 | 2.68x |
| 2025-11-12 | 2.71x |
| 2025-11-11 | 2.73x |
| 2025-11-10 | 2.68x |
| 2025-11-07 | 2.67x |
| 2025-11-06 | 2.70x |
| 2025-11-05 | 2.66x |
| 2025-11-04 | 2.82x |
| 2025-11-03 | 2.84x |
| 2025-10-31 | 2.85x |
| 2025-10-30 | 2.84x |
| 2025-10-29 | 2.85x |
| 2025-10-28 | 2.95x |
| 2025-10-27 | 3.04x |
| 2025-10-24 | 3.06x |
| 2025-10-23 | 2.98x |
| 2025-10-22 | 2.94x |
| 2025-10-21 | 2.95x |
| 2025-10-20 | 2.90x |
| 2025-10-17 | 2.83x |
| 2025-10-16 | 2.79x |
| 2025-10-15 | 2.74x |
| 2025-10-14 | 2.73x |
| 2025-10-13 | 2.74x |
| 2025-10-10 | 2.69x |
| 2025-10-09 | 2.75x |
| 2025-10-08 | 2.77x |
| 2025-10-07 | 2.73x |
| 2025-10-06 | 2.79x |
| 2025-10-03 | 2.82x |
| 2025-10-02 | 2.79x |
| 2025-10-01 | 2.73x |
| 2025-09-30 | 2.56x |
| 2025-09-29 | 2.45x |
| 2025-09-26 | 2.46x |
| 2025-09-25 | 2.43x |
| 2025-09-24 | 2.48x |
| 2025-09-23 | 2.49x |
| 2025-09-22 | 2.53x |
| 2025-09-19 | 2.55x |
| 2025-09-18 | 2.57x |
| 2025-09-17 | 2.52x |
| 2025-09-16 | 2.50x |
| 2025-09-15 | 2.51x |
| 2025-09-12 | 2.52x |
| 2025-09-11 | 2.60x |
| 2025-09-10 | 2.52x |
| 2025-09-09 | 2.57x |
| 2025-09-08 | 2.63x |
| 2025-09-05 | 2.65x |
| 2025-09-04 | 2.63x |
| 2025-09-03 | 2.63x |
| 2025-09-02 | 2.62x |
| 2025-08-29 | 2.65x |
| 2025-08-28 | 2.64x |
| 2025-08-27 | 2.64x |
| 2025-08-26 | 2.65x |
| 2025-08-25 | 2.66x |
| 2025-08-22 | 2.63x |
| 2025-08-21 | 2.54x |
| 2025-08-20 | 2.60x |
| 2025-08-19 | 2.59x |
| 2025-08-18 | 2.57x |
| 2025-08-15 | 2.56x |
| 2025-08-14 | 2.55x |
| 2025-08-13 | 2.54x |
| 2025-08-12 | 2.52x |
| 2025-08-11 | 2.47x |
| 2025-08-08 | 2.47x |
| 2025-08-07 | 2.48x |
| 2025-08-06 | 2.49x |
| 2025-08-05 | 2.80x |
| 2025-08-04 | 2.81x |
| 2025-08-01 | 2.80x |
| 2025-07-31 | 2.83x |
| 2025-07-30 | 2.91x |
| 2025-07-29 | 2.94x |
| 2025-07-28 | 2.95x |
| 2025-07-25 | 2.92x |
| 2025-07-24 | 2.92x |
| 2025-07-23 | 2.81x |
| 2025-07-22 | 2.75x |
| 2025-07-21 | 2.58x |
| 2025-07-18 | 2.64x |
| 2025-07-17 | 2.67x |
| 2025-07-16 | 2.64x |
| 2025-07-15 | 2.64x |
| 2025-07-14 | 2.68x |
| 2025-07-11 | 2.70x |
| 2025-07-10 | 2.75x |
| 2025-07-09 | 2.69x |
| 2025-07-08 | 2.69x |
| 2025-07-07 | 2.63x |
| 2025-07-03 | 2.67x |
| 2025-07-02 | 2.68x |
| 2025-07-01 | 2.64x |
| 2025-06-30 | 2.60x |
| 2025-06-27 | 2.58x |
| 2025-06-26 | 2.60x |
| 2025-06-25 | 2.58x |
| 2025-06-24 | 2.56x |
| 2025-06-23 | 2.55x |
| 2025-06-20 | 2.55x |
| 2025-06-18 | 2.52x |
| 2025-06-17 | 2.52x |
| 2025-06-16 | 2.59x |
| 2025-06-13 | 2.57x |
| 2025-06-12 | 2.61x |
| 2025-06-11 | 2.60x |
| 2025-06-10 | 2.59x |
| 2025-06-09 | 2.55x |
| 2025-06-06 | 2.51x |
| 2025-06-05 | 2.47x |
| 2025-06-04 | 2.50x |
| 2025-06-03 | 2.44x |
| 2025-06-02 | 2.39x |
| 2025-05-30 | 2.40x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James C. Foster